| 产品描述: | COX-2 选择性抑制剂;COX-2 Selective Inhibitors;;InformationMavacoxib (Trocoxil) is a selective, long-actingcyclooxygenase-2 (COX-2)inhibitor. Mavacoxib is a novel nonsteroidal anti-inflammatory drug (NSAID).TargetsCOX-2 |
| 体内研究: |
Osteoarthritic dogs enrolled in the studies are randomized to receive treatment with Mavacoxib and daily placebo for carprofen or placebo for Mavacoxib and daily carprofen at a nominal dose of 4 mg/kg BW. Mavacoxib is administered in both studies with a 2-week interval between the first and second doses but with monthly dosing thereafter. The nominal Mavacoxib doses in Studies 1 and 2 are 4 and 2 mg/kg BW, respectively. Seven Mavacoxib doses are administered in Study 1, but only five doses in Study 2. In Study 1, Mavacoxib is administered without regard to the timing of meals, but in Study 2, all of the Mavacoxib doses are administered with food. |
| 参考文献: |
1. Hurst EA, et al. The selective cyclooxygenase-2 inhibitor mavacoxib (Trocoxil) exerts anti-tumour effects in vitro independent of cyclooxygenase-2 expression levels. Vet Comp Oncol. 2019 Jun;17(2):194-207. 2. Cox SR, et al. Population pharmacokinetics of mavacoxib in osteoarthritic dogs. J Vet Pharmacol Ther. 2011 Feb;34(1):1-11. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.595 ml |
12.976 ml |
25.951 ml |
| 5 mM |
0.519 ml |
2.595 ml |
5.19 ml |
| 10 mM |
0.26 ml |
1.298 ml |
2.595 ml |
| 50 mM |
0.052 ml |
0.26 ml |
0.519 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |